共查询到20条相似文献,搜索用时 46 毫秒
1.
《Journal of medical economics》2013,16(8):573-585
Abstract
Background:
Lixisenatide is a potent, selective and short-acting once daily prandial glucagon-like peptide-1 receptor agonist which lowers glycohemoglobin and body weight by clinically significant amounts in patients with type 2 diabetes treated with basal insulin, with limited risk of hypoglycemia. 相似文献2.
《Journal of medical economics》2013,16(7):542-549
Abstract
Objectives:
Few studies have evaluated the economic burden of surgical and conservative treatment of fracture non-union. An analysis was undertaken of aggregated payer data to determine economic costs of non-unions treated with surgery only vs non-unions treated conservatively with low-intensity pulsed ultrasound (LIPUS) only. 相似文献3.
《Journal of medical economics》2013,16(9):666-677
Abstract
Objective:
To compare healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus (T2DM) in the United States newly initiating exenatide once weekly (QW) or liraglutide. 相似文献4.
《Journal of medical economics》2013,16(6):420-432
Abstract
Objective:
To identify the direct and indirect costs of hypoglycemia in patients with Type 1 or Type 2 diabetes mellitus (DM) in the US setting. 相似文献5.
《Journal of medical economics》2013,16(2):249-259
Abstract
Objective:
To evaluate the financial consequences of using laparoscopic adjustable gastric banding (LAGB) in place of standard medical management (SMM) in obese patients with type 2 diabetes from a UK healthcare payer perspective. 相似文献6.
《Journal of medical economics》2013,16(10):821-827
Abstract
Objective:
Bipolar disorder imposes a high economic burden on patients and society. Lurasidone and quetiapine extended-release (XR) are atypical antipsychotic agents indicated for monotherapy treatment of bipolar depression. Lurasidone is also indicated as adjunctive therapy with lithium or valproate for depressive episodes associated with bipolar disorder. The objective of this analysis was to estimate the cost-effectiveness of lurasidone and quetiapine XR in patients with bipolar depression. 相似文献7.
《Journal of medical economics》2013,16(1):150-159
Abstract
Background:
Recent clinical trial data have demonstrated that 3 years vs 1 year of adjuvant imatinib therapy for patients with surgically resected Kit+ Gastrointestinal Stromal Tumors (GIST) leads to a significant improvement in recurrence-free survival and overall survival. This study assesses the cost-effectiveness of treating patients with 3 years vs 1 year of imatinib from a US payer’s perspective. 相似文献8.
《Journal of medical economics》2013,16(11):874-885
Abstract
Objective:
The cost-effectiveness of new oral disease-modifying therapies (DMTs) has not been modeled in highly active (HA) relapsing-remitting multiple sclerosis (RRMS) requiring escalation therapy. This study sought to model the cost-effectiveness of fingolimod compared to dimethyl fumarate (DMF), for which relevant HA RRMS sub-group data were available, from the perspective of the National Health Service (NHS) in England. 相似文献9.
《Journal of medical economics》2013,16(10):808-820
Abstract
Objective:
This study aims to estimate the long-term cost-effectiveness of saxagliptin?+?metformin (SAXA?+?MET) vs glimepiride?+?metformin (GLI?+?MET) in patients with Type 2 diabetes mellitus (T2DM) inadequately controlled with MET in China. 相似文献10.
《Journal of medical economics》2013,16(12):1032-1040
Abstract
Objective:
To quantify the cost of acute major adverse cardiac events (MACE; myocardial infarction [MI] and stroke) stratified by cardiovascular disease (CVD) risk factors in commercially, Medicare Supplemental-, and Medicaid-insured patients with type 2 diabetes mellitus (T2DM). 相似文献11.
《Journal of medical economics》2013,16(2):278-288
Abstract
Objective:
To estimate the budget impact of everolimus as the first and second treatment option after letrozole or anastrozole (L/A) failure for post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC). 相似文献12.
《Journal of medical economics》2013,16(7):550-563
Abstract
Background:
Asthma and chronic obstructive pulmonary disease (COPD) are incurable diseases that impact quality-of-life. 相似文献13.
《Journal of medical economics》2013,16(8):637-645
Abstract
Objective:
Conduct a cost effectiveness analysis for the Paliperidone palmitate Research In Demonstrating Effectiveness (PRIDE) trial. 相似文献14.
《Journal of medical economics》2013,16(2):202-212
Abstract
Objective:
To estimate the cost-effectiveness of ipilimumab (3?mg/kg) compared with best supportive care (BSC) in pre-treated advanced melanoma patients. 相似文献15.
《Journal of medical economics》2013,16(6):410-419
Abstract
Objectives:
To project the cost-effectiveness of population-based echo screening to prevent rheumatic heart disease (RHD) consequences. 相似文献16.
《Journal of medical economics》2013,16(11):898-908
Abstract
Objective:
To compare healthcare resource utilization (HCRU) and healthcare costs in patients with acute coronary syndrome (ACS) managed with percutaneous coronary intervention (PCI) and treated with prasugrel or ticagrelor. 相似文献17.
《Journal of medical economics》2013,16(1):179-189
Abstract
Objective
This retrospective observational study describes treatment patterns and longitudinal health-related quality-of-life (HRQoL) among metastatic breast cancer patients with bone metastasis from nine community oncology clinics. 相似文献18.
《Journal of medical economics》2013,16(2):231-239
Abstract
Objective:
To compare hospitalizations and incidence of relapses among patients with schizophrenia initiating long-acting injectable (LAI) antipsychotics vs oral antipsychotics. 相似文献19.
《Journal of medical economics》2013,16(5):349-356
Abstract
Objective:
To estimate direct medical costs for patients with tuberous sclerosis complex (TSC) and surgical resection of subependymal giant-cell astrocytoma (SEGA). 相似文献20.
《Journal of medical economics》2013,16(2):298-306
Abstract